VYNE Therapeutics (VYNE) Other Working Capital Changes (2017 - 2026)
VYNE Therapeutics (VYNE) posted Other Working Capital Changes of -$37000.0 for Q2 2025, little changed on a QoQ basis from -$37000.0 in Q1 2025, and down 5.71% year-over-year from -$39242.4 in Q2 2024.
VYNE Therapeutics (VYNE) Other Working Capital Changes (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Other Working Capital Changes history runs 9 years deep, the most recent figure standing at -$37000.0 for Q2 2025.
- Quarterly Other Working Capital Changes fell 5.71% year-over-year to -$37000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$97000.0 (up 17.09% YoY) and the FY2025 annual result came in at -$99000.0, up 13.16% from the prior year.
- Other Working Capital Changes was -$37000.0 for Q2 2025 at VYNE Therapeutics, roughly flat from -$37000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $2.8 million in Q2 2024 and bottomed at -$9.5 million in Q4 2022.
- A 5-year average of -$809769.2 and a median of -$492000.0 in 2023 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2021 — Other Working Capital Changes tumbled 120700.0% — and 2025, when it decreased 5.71%.
- VYNE Therapeutics' Other Working Capital Changes stood at -$1.2 million in 2021, then soared by 97.43% to -$31000.0 in 2022, then soared by 790.32% to $214000.0 in 2023, then tumbled by 110.75% to -$23000.0 in 2024, then slumped by 60.87% to -$37000.0 in 2025.
- Business Quant data shows VYNE's Other Working Capital Changes at -$37000.0 in Q2 2025, -$37000.0 in Q1 2025, and -$23000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -202,000.00 |
| Mar 31, 2026 | -202,000.00 |
| Mar 31, 2026 | -202,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 768,000.00 |
| Mar 31, 2025 | 768,000.00 |
| Mar 31, 2025 | 768,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Dec 31, 2024 | -688,000.00 |
| Sep 30, 2024 | -2.54 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Sep 30, 2024 | -2.54 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |